Narimon Honarpour

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Narimon Honarpour, Dirk Blom et al. · The Lancet · 2014 · 720 citations

Metabolic Syndrome, Lipid Disorder, Homozygous Familial Hypercholesterolaemia +11

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

John R. Teerlink, Rafael Díaz, G. Michael Felker et al. · New England Journal of Medicine · 2020 · 625 citations · Full text

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Marc S. Sabatine, Lawrence A. Leiter, Stephen D. Wiviott et al. · The Lancet Diabetes & Endocrinology · 2017 · 578 citations · Full text

Metabolic Syndrome, Hypertension, Diabetes Management +10

Cognitive Function in a Randomized Trial of Evolocumab

Robert P. Giugliano, François Mach, Kenton H. Zavitz et al. · New England Journal of Medicine · 2017 · 466 citations · Full text

Neuropsychology, Cognition, Cognitive Rehabilitation +19

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Evan A. Stein, Narimon Honarpour, Scott M. Wasserman et al. · Circulation · 2013 · 327 citations · Full text